Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252) has announced that it has received marketing approval from the National Medical Products Administration (NMPA) for the ISR’obot Mona Lisa prostate puncture robot positioning system. This product is a result of a joint venture between MicroPort MedBot and Biobot Surgical Pte. Ltd, based in China.
Innovation in Prostate Puncture Robotics
The Mona Lisa system is self-described as the first prostate puncture robot in the field of urology in China. This innovative technology has the potential to significantly improve the positive detection rate of patients by reducing manual errors and missed diagnosis rates. The system assists clinical doctors in completing puncture biopsies more accurately and efficiently, which can lead to better patient outcomes.
Enhancing Patient Experience and Clinical Efficiency
By lessening patient pain and streamlining the biopsy process, the Mona Lisa system contributes to a more patient-friendly and efficient clinical environment. The approval from the NMPA marks a significant step forward in the application of robotic technology in urological procedures, offering a new standard for prostate puncture in China.-Fineline Info & Tech
